| 1 |
34779641 | Prediction model based on 18F-FDG PET/CT radiomic features and clinical factors of EGFR mutations in lung adenocarcinoma. | 2022 Jan |
1 |
| 2 |
34908022 | Correlation of epidermal growth factor receptor mutation status and PD-L1 expression with [18F]FDG PET using volume-based parameters in non-small cell lung cancer. | 2022 Mar 1 |
1 |
| 3 |
34954763 | Lung adenocarcinoma: development of nomograms based on PET/CT images for prediction of epidermal growth factor receptor mutation status and subtypes. | 2022 Mar 1 |
2 |
| 4 |
35084711 | Predictive value of multiple metabolic and heterogeneity parameters of 18F-FDG PET/CT for EGFR mutations in non-small cell lung cancer. | 2022 Apr |
5 |
| 5 |
35326662 | 18F-Fluorodeoxyglucose PET/CT for Early Prediction of Outcomes in Patients with Advanced Lung Adenocarcinomas and EGFR Mutations Treated with First-Line EGFR-TKIs. | 2022 Mar 15 |
5 |
| 6 |
35420272 | Efficient 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography-based machine learning model for predicting epidermal growth factor receptor mutations in non-small cell lung cancer. | 2022 Apr 14 |
6 |
| 7 |
35515138 | A Review of the Correlation Between Epidermal Growth Factor Receptor Mutation Status and 18F-FDG Metabolic Activity in Non-Small Cell Lung Cancer. | 2022 |
2 |
| 8 |
32063026 | Radiogenomic Models Using Machine Learning Techniques to Predict EGFR Mutations in Non-Small Cell Lung Cancer. | 2021 Feb |
2 |
| 9 |
33568935 | Biological Significance of 18F-FDG PET/CT Maximum Standard Uptake Value for Predicting EGFR Mutation Status in Non-Small Cell Lung Cancer Patients. | 2021 |
1 |
| 10 |
34062472 | The diagnostic and predictive efficacy of 18F-FDG PET/CT metabolic parameters for EGFR mutation status in non-small-cell lung cancer: A meta-analysis. | 2021 Aug |
3 |
| 11 |
34103313 | Can 18F-FDG PET/CT predict EGFR status in patients with non-small cell lung cancer? A systematic review and meta-analysis. | 2021 Jun 8 |
5 |
| 12 |
34367993 | Prediction of EGFR Mutation Status Based on 18F-FDG PET/CT Imaging Using Deep Learning-Based Model in Lung Adenocarcinoma. | 2021 |
6 |
| 13 |
34557420 | Corrigendum: Prediction of EGFR Mutation Status Based on 18F-FDG PET/CT Imaging Using Deep Learning-Based Model in Lung Adenocarcinoma. | 2021 |
1 |
| 14 |
34957737 | Relationship between 18F-FDG PET/CT radiometabolic markers and EGFR mutation, positive ALK Expression in patients with non-small cell lung cancer. | 2021 Dec |
2 |
| 15 |
31659591 | Usefulness of gradient tree boosting for predicting histological subtype and EGFR mutation status of non-small cell lung cancer on 18F FDG-PET/CT. | 2020 Jan |
1 |
| 16 |
32676319 | Predicting EGFR mutation subtypes in lung adenocarcinoma using 18F-FDG PET/CT radiomic features. | 2020 Jun |
3 |
| 17 |
32676320 | 18F-fluorodeoxyglucose positron emission tomography/computed tomography-based radiomic features for prediction of epidermal growth factor receptor mutation status and prognosis in patients with lung adenocarcinoma. | 2020 Jun |
1 |
| 18 |
32742498 | Value of combining PET/CT and clinicopathological features in predicting EGFR mutation in Lung Adenocarcinoma with Bone Metastasis. | 2020 |
1 |
| 19 |
32801885 | Diagnostic and Predictive Values of 18F-FDG PET/CT Metabolic Parameters in EGFR-Mutated Advanced Lung Adenocarcinoma. | 2020 |
6 |
| 20 |
32815896 | Primary metabolic tumor volume from 18F-FDG PET/CT associated with epidermal growth factor receptor mutation in lung adenocarcinoma patients. | 2020 Nov |
1 |
| 21 |
32831963 | Relationship of EGFR Mutation to Glucose Metabolic Activity and Asphericity of Metabolic Tumor Volume in Lung Adenocarcinoma. | 2020 Aug |
1 |
| 22 |
32863894 | 18F-FDG PET/CT SUVmax and serum CEA levels as predictors for EGFR mutation state in Chinese patients with non-small cell lung cancer. | 2020 Oct |
3 |
| 23 |
33011375 | Value of interim 18F-FDG PET/CT for predicting progression-free survival in stage ⅢB/IV EGFR-mutant non-small-cell lung cancer patients with EGFR-TKI therapy. | 2020 Nov |
3 |
| 24 |
33067442 | Non-invasive decision support for NSCLC treatment using PET/CT radiomics. | 2020 Oct 16 |
1 |
| 25 |
33134170 | Performance of 18F-FDG PET/CT Radiomics for Predicting EGFR Mutation Status in Patients With Non-Small Cell Lung Cancer. | 2020 |
4 |
| 26 |
33262942 | Value of 18F-FDG PET/CT-Based Radiomics Nomogram to Predict Survival Outcomes and Guide Personalized Targeted Therapy in Lung Adenocarcinoma With EGFR Mutations. | 2020 |
1 |
| 27 |
33370365 | Incorporating radiomic feature of pretreatment 18F-FDG PET improves survival stratification in patients with EGFR-mutated lung adenocarcinoma. | 2020 |
3 |
| 28 |
30320488 | CD147-mediated glucose metabolic regulation contributes to the predictive role of 18 F-FDG PET/CT imaging for EGFR-TKI treatment sensitivity in NSCLC. | 2019 Feb |
1 |
| 29 |
30431083 | EGFR mutation decreases FDG uptake in non‑small cell lung cancer via the NOX4/ROS/GLUT1 axis. | 2019 Jan |
4 |
| 30 |
30776196 | Correlation between EGFR mutation status and F18 -fluorodeoxyglucose positron emission tomography-computed tomography image features in lung adenocarcinoma. | 2019 Apr |
2 |
| 31 |
31126985 | Increased 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3 activity in response to EGFR signaling contributes to non-small cell lung cancer cell survival. | 2019 Jul 5 |
1 |
| 32 |
31532771 | EGF receptor stimulation shifts breast cancer cell glucose metabolism toward glycolytic flux through PI3 kinase signaling. | 2019 |
3 |
| 33 |
31681597 | Predictive Power of a Radiomic Signature Based on 18F-FDG PET/CT Images for EGFR Mutational Status in NSCLC. | 2019 |
1 |
| 34 |
29547059 | Relation of EGFR Mutation Status to Metabolic Activity in Localized Lung Adenocarcinoma and Its Influence on the Use of FDG PET/CT Parameters in Prognosis. | 2018 Jun |
2 |
| 35 |
28881771 | Prediction of EGFR and KRAS mutation in non-small cell lung cancer using quantitative 18F FDG-PET/CT metrics. | 2017 Aug 8 |
2 |
| 36 |
26632406 | Relationship between Preoperative ¹⁸F-Fluorodeoxyglucose Uptake and Epidermal Growth Factor Receptor Status in Primary Colorectal Cancer. | 2016 Jan |
3 |
| 37 |
26998075 | Association between histopathological subtype, 18F-fluorodeoxyglucose uptake and epidermal growth factor receptor mutations in lung adenocarcinoma. | 2016 Mar |
5 |
| 38 |
27597275 | Standardized uptake value on (18)F-FDG-PET/CT is a predictor of EGFR T790M mutation status in patients with acquired resistance to EGFR-TKIs. | 2016 Oct |
1 |
| 39 |
26359571 | FDG uptake in non-small cell lung cancer is not an independent predictor of EGFR or KRAS mutation status: a retrospective analysis of 206 patients. | 2015 Dec |
2 |
| 40 |
24852187 | Value of ¹⁸F-FDG uptake on PET/CT and CEA level to predict epidermal growth factor receptor mutations in pulmonary adenocarcinoma. | 2014 Oct |
1 |
| 41 |
23489365 | FDG-PET SUV-max values do not correlate with epidermal growth factor receptor mutation status in lung adenocarcinoma. | 2013 May |
1 |
| 42 |
21339258 | Role of 18F-fluorodeoxyglucose positron emission tomography in predicting epidermal growth factor receptor mutations in non-small cell lung cancer. | 2011 |
2 |
| 43 |
17020967 | Monitoring tumor glucose utilization by positron emission tomography for the prediction of treatment response to epidermal growth factor receptor kinase inhibitors. | 2006 Oct 1 |
2 |